Cognition Therapeutics (CGTX) Life Sciences Investor Forum summary

Company overview and strategy

• Focuses on developing oral therapies for neurodegenerative diseases, including Alzheimer's, Lewy body dementia, and dry AMD.

• Operates with a lean team of under 30 people and has received over $200 million in grant funding.

• Emphasizes capital efficiency and significant upcoming clinical catalysts.

• Completed a public offering in October 2021.

Clinical trial results and pipeline

• SHINE phase II trial in mild to moderate Alzheimer's showed 39% slowing of cognitive decline and up to 70% on certain measures.

• Patients with low baseline tau had 95% slowing of decline, with some showing no cognitive deterioration.

• Drug demonstrated a favorable safety profile, with adverse events similar to placebo.

• Phase III planning underway, with input from FDA and external advisors.

• Additional phase II trials ongoing in early Alzheimer's (START), Lewy body dementia, and dry AMD (MAGNIFY).

Differentiation and physician feedback

• Oral, once-daily administration offers simplicity over monoclonal antibody treatments.

• No ARIA risk, eliminating need for imaging surveillance.

• Physicians rated efficacy and safety highly, with some calling results as good or better than monoclonal antibodies.

• Drug can be used alongside existing Alzheimer's therapies.